March 3, 2026Open Access

Pembrolizumab-Induced Primary Adrenal Insufficiency: A Rare But Life-Threatening Endocrine irAE

Puntos clave

Primary adrenal insufficiency can arise from pembrolizumab treatment, posing significant health risks.
Early recognition of primary adrenal insufficiency is vital for effective intervention and management.
Analysis of a case involving a 75-year-old man showcases the clinical impact of this rare endocrine disorder.
Awareness of immune-related adverse events is crucial in improving patient outcomes during immunotherapy.

Resumen

Pembrolizumab, a PD-1 checkpoint inhibitor, is widely used in the treatment of various malignancies. While it improves overall survival, it can lead to immune-related adverse events (irAEs), including rare endocrine disorders such as primary adrenal insufficiency (PAI). We present a case of PAI induced by Pembrolizumab in a 75-year-old man, emphasizing the importance of early recognition and timely management.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Syeda Sarah Raza

Mehr A Orakzai

Abdullah A Orakzai

Journals

Advances in Clinical Medical Research and Healthcare Delivery

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Pembrolizumab-Induced Primary Adrenal Insufficiency: A Rare But Life-Threatening Endocrine irAE

Puntos clave

Resumen

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study